Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302

05 Oct 2021  |  08:29:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Opthea's Phase 3 open for patient recruitment in Europe

Opthea announced that enrollment for its Phase 3 pivotal clinical program of OPT-302 for the treatment of wet (neovascular) age-related macular degeneration (AMD) is open in Europe. The two concurrent global Phase 3 registrational clinical trials, ShORe (Study of OPT-302 in combination with Ranibizumab) and COAST (Combination OPT-302 with Aflibercept Study) will be conducted in up to 20 countries across Europe. The ShORe and COAST registrational studies are expected to each enroll 990 treatment naive patients and are evaluating OPT-302 combination therapy as a potential treatment for wet AMD. Enrollment has been ongoing in the U.S. and Canada and is being expanded into Europe and the rest of the world.

Please click here for full details

See more ASX300 News Announcements